Does oral creatine supplementation enhance recovery from a worsening of chronic bronchitis?

Does oral creatine supplementation enhance recovery from chronic obstructive pulmonary disease (COPD) exacerbation?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN22287730

Enrollment

Registered

2008-03-19

Start date

2007-05-29

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Chronic obstructive pulmonary disease

Interventions

The study will have two arms: 1. Standard care with placebo: This will comprise best clinical practice defined by National Institute for Clinical Excellence (NICE) (Clinical Guideline 12: "Managemen

Eligibility

Inclusion criteria

Inclusion criteria: 1. Chronic obstructive pulmonary disease (COPD) 2. Acute exacerbation COPD

Exclusion criteria

Exclusion criteria: 1. Alternative diagnosis for acute presentation 2. Active cardiac, neurological, neoplastic disease 3. Diabetes 4. Significant locomotor disease 5. Renal or hepatic impairment 6. Persisting decompensated respiratory acidosis 7. Depressed cognitive function 8. Terminal condition 9. Pregnant, lactating, or wish to become pregnant 10. Implanted cardiac pacemaker resynchronise or defibrillator device 11. Enteral route contraindicated

Design outcomes

Primary

Measure	Time frame
Fat free mass, measured at baseline and after treatment (2/52; or 42 doses)	—

Secondary

Measure	Time frame
1. Anthropometry 2. Hand-grip and strength 3. Maximal expiratory pressure (MEP)/maximal inspiratory pressure (MIP)/sniff nasal inspiratory pressure (SNIP) 4. Rise to go test 5. Six minute walk test (SMWT) 6. High sensitivity C-reactive protein (hsCRP) 7. Interleukin-six (IL-6) 8. Tumour necrosis factor-alpha (TNF-a) 9. Digit span 10. Medical Research Council (MRC) dyspnoea scale 11. Hospital Anxiety and Depression (HAD) score 12. London Chest Activity of Daily Living (LCADL) score 13. Baseline/Transition Dyspnoea Index (BDI/TDI) All endpoints measured at baseline and after treatment (2/52; or 42 doses)	—

Measure

Time frame

1. Anthropometry 2. Hand-grip and strength 3. Maximal expiratory pressure (MEP)/maximal inspiratory pressure (MIP)/sniff nasal inspiratory pressure (SNIP) 4. Rise to go test 5. Six minute walk test (SMWT) 6. High sensitivity C-reactive protein (hsCRP) 7. Interleukin-six (IL-6) 8. Tumour necrosis factor-alpha (TNF-a) 9. Digit span 10. Medical Research Council (MRC) dyspnoea scale 11. Hospital Anxiety and Depression (HAD) score 12. London Chest Activity of Daily Living (LCADL) score 13. Baseline/Transition Dyspnoea Index (BDI/TDI) All endpoints measured at baseline and after treatment (2/52; or 42 doses)

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026